STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma: We conclude that small‐molecule STAT3/5 degraders and IQDMA, as a broad‐range kinase inhibitor, or the more selective PAK inhibitor, represent effective drugs to battle L‐CTCL.